New or updated compounds/ Category or Study/ AI(ng/day)
5-chloro-4-methyl-2-[(2S)-2-methyl-1-nitrosopyrrolidin-2-yl]-1H-benzimidazole/ Cat.5/ 1500
N-nitroso-ambroxol/ EAT? Nega/ 1500
N-nitroso-calcium folinate/ in vivo Nega/ NMI
N-nitroso-celiprolol/ Cat.5/ 1500
N-nitroso-desethyllidocaine/ Cat.2/ 100
N-nitroso-desmethyl-azelastine/ Cat.2/ 100
N-nitroso-desvenlafaxine/ Cat.1/ 18
N-nitroso-dorzolamide/ Cat.2/ 100
N-nitroso-esmolol/ Cat.4/ 1500
N-nitroso-ethylenediamine-triacetic acid/ Cat.4/ 1500
N-nitroso-iminodiacetic acid/ Cat.4/ 1500
N-nitroso-indapamide/ Cat.5/ 1500
N-nitroso-leniolisib/ Cat.5/ 1500
N-nitroso-N-methylaniline(NMPA)/ Cat.2/ 100
N-nitroso-tetracaine/ Cat.3/ 400
N-Nitroso-ticagrelor/ Cat.5/ 1500
NMPA is updated from 34.3ng/day to Cat.2(100ng/day).
Interestingly, Nitroso-Indapamide = Indapamide Impurity A is included in the Ph. Eur. Indapamide monograph with a limit of 5 ppm. It appears as a contradiction to deal with.
There was a previous discussion on the topic on the site
N-Nitrosoiminodiacetic acid and N-nitroso-ethylenediamine-triacetic acid are included with an AI of 1.5µg/day, originating from Isosorbide mononitrate. N-Nitrosoiminodiacetic acid has negative data in LCDB, however they are not considered reliable.
My answer for the indapamide case would be the same as in that thread - the monograph limits appear to be limits based on achievable quality standards and the existing batches on the market (independent of the toxicity of the impurities, there is real value in having drug substances as pure and well-characterised as possible) rather than the safety-threshold-determined limit that would be permissible under the CPCA or any other guidance.
So NMPA has moved from a limit of 34.3 ng/day to 100 ng/day based upon it falling into Category 2 if you put it through the CPCA calculation.
Does this mean that we could see the limit changing for NMPA from the FDA as well, where it is still currently 26.5 ng/day?
I hadn’t considered putting the original small molecules back through the calculation.
(and thanks to all that have contribute until now, particularly Yosukemino ¡! )
Apart of the format change (PDF to Excel Table)…some new columns added or am I driving crazy? e.g. I do not remember seeing “Structures” in previous list in PDF
Indeed, now structures, that is more visually appealing
Smiles are very useful for searching nitrosamines in QSAR and DB. Similarity search is also available for read-across. That’s great progress!!
As far as I know, the FDA never changed the AI from the original except for the interim limit. The AI of varenicline is still different between FDA and EMA(37 vs 400). And NMPA is separated from NDSRIs.
As @conudel explained in the webinar today, there are lots of gaps in policy between the FDA and the EMA. We should pay attention to the FDA’s next approach.
It was fantastic presentation by @conudel today. I hope Lhasa made available the recording soon, the cases and the regulatory gaps was very insightful.
One of the reasons, something not as harsh to perfom as a carcinogenic study is needed. The nitrosamine topic is still long to be solved.
The CPCA even with its limitations helped quite a bit. But this is one of the reasons the joint cooperation between industry and regulators is needed. To focus a bit more on positive Ames compounds rather than putting efforts on compounds that are out of the CoC. Where nonetheless, more evidence is coming of certain drug classes for example.
Here is the link to Lhasa webinar “How to establish acceptable intake limits for NDSRIs” 22nd Nov 2023
How to establish acceptable intake limits for NDSRIs (vimeo.com)